Comment prendre en charge les tumeurs carcinoïdes gastriques ?

详细信息    查看全文

• 作者：G. Cadiot ; H. Brixi ; A. Marchal ; M. -D. Diebold
• 关键词：Neuroendocrine tumor ; Stomach ; Pernicious anemia ; Biermer’s disease ; Zollinger ; Ellison syndrome ; Multiple endocrine neoplasia type 1 ; Proton pump inhibitor
• 刊名：Acta Endoscopica
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：46
• 期：3
• 页码：196-199
• 全文大小：115 KB
• 参考文献：1.Scherübl H, Cadiot G, Jensen RT, et al. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 2010;42:664–71.CrossRef PubMed
  2.de Mestier L, Diebold MD, Cadiot G. La maladie de Biermer. Hepato Gastro 2014;21:595–606.
  3.de Mestier L, Diebold MD, Devulder F, et al. Gastric carcinoids escaping the currently available classification. Scand J Gastroenterol 2015;50:621–2.CrossRef PubMed
  4.Kim HH, Kim GH, Kim JH, et al. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract 2014;2014:253860.PubMed PubMedCentral
  5.Jianu CS, Fossmark R, Syversen U, et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol 2011;46:456–63.CrossRef PubMed
  6.Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 2013;19:8703–8.CrossRef PubMed PubMedCentral
  
• 作者单位：G. Cadiot (1)
  H. Brixi (1)
  A. Marchal (2)
  M. -D. Diebold (2)
  
  1. Service d’hépatogastroentérologie et de cancérologie digestive, hôpital Robert Debré, CHU de Reims, F-51092, Reims cedex, France
  2. Laboratoire de biopathologie, hôpital Robert Debré, CHU de Reims, F-51092, Reims cedex, France
  
• 刊物主题：Gastroenterology; Interventional Radiology; Abdominal Surgery; Oncology; Gynecology; Urology/Andrology;
• 出版者：Springer Paris
• ISSN：1958-5454

文摘

Most gastric well-differentiated neuroendocrine tumors (NETs) are located in the corpus part of the stomach. Two types are frequent: type 1 which is associated with autoimmune fundic atrophic gastritis due to the pernicious anemia where hypergastrinemia triggers fundic endocrine cell hyperplasia then NETs and type 3 (sporadic NETs) without any underlying disease (no hypergastrinemia, no fundic atrophic gastritis, no fundic endocrine cell hyperplasia). Most type 1 gastric NETs are benign, multiple, small (<1 cm) and are either not resected or endoscopically resected. Morphological investigations (endoscopic ultrasound, somatostatin receptor scintigraphy) are only indicated for tumors >1 cm. Type 3 NETs are most often invasive, malignant and must be managed as cancers of similar size. Type 2 NETs associated with the Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 are very rare. These underlying diseases are always known before gastric NETs diagnosis. The main aims of the management of welldifferentiated NETs are first to differentiate types 1 and 3, i.e. to search for pernicious anemia, and secondly to be harmless due to the benignity of type 1 tumors.